The Aducanumab Aftermath: The Payer

A controversial new $56,000 Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.

This episode is part of a special weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.


Mark Miller, PhD, Executive Vice President for Health Care, Arnold Ventures

Explore the full series and additional resources:

Read a transcript of this episode:

Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff:

Support this type of journalism today, with a gift:

Follow us on Twitter:

See for privacy and opt-out information.